New appetite drug for weight loss in advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer that has not been treated with chemotherapy for spread disease.
- You have lost weight without trying or have a low body weight along with signs of inflammation.
- You are between 18 and 75 years old and in reasonably good health (able to do daily activities).
- You are not taking other drugs that boost appetite or weight, and you have no serious stomach or gut problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new form of megestrol acetate (a medication that helps stimulate appetite and weight gain) for people with advanced liver cancer who are experiencing weight loss or loss of appetite. It is given alongside standard treatments for liver cancer, and the goal is to see if it can improve appetite and quality of life.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This trial tests whether a drug called nanocrystalline megestrol acetate can help improve appetite and weight loss in people with advanced liver cancer. It is given as a pill and is compared against a placebo (a pill with no active medicine).
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This study tests a special form of the drug megestrol acetate (Megace) in cancer patients who have lost weight and appetite (cachexia). It aims to see if this medication can help improve weight gain and quality of life.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
Hear when a new Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.